|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00060515 |
|
Date of registration:
|
07/05/2003 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
|
|
Scientific title:
|
An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases |
|
Date of first enrolment:
|
April 2003 |
|
Target sample size:
|
12 |
|
Recruitment status: |
Terminated |
|
URL:
|
http://clinicaltrials.gov/show/NCT00060515 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Primary Purpose: Treatment
|
|
Phase:
|
Phase 1
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Mitochondrial Disease
Age minimum:
3 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Mitochondrial Diseases
|
|
Intervention(s)
|
|
Drug: RG2133 (2',3',5'-tri-O-acetyluridine)
|
|
Secondary ID(s)
|
|
RG2133-01
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|